Cough Clinical Trial
Official title:
Randomized Clinical Trial Evaluating the Non-clinical Inferiority of Suppository Transpulmin and Suppository Guaiacol Compared to Transpulmin Syrup in Frames of Productive Cough of Infectious Origin in Pediatric Participants.
This study evaluates the non-inferiority of Suppository Transpulmin and Suppository Guaiacol compared to Transpulmin Syrup in the treatment of cough with secretion of infectious origin in children between two and six years old. One third of participants will receive Suppository Transpulmin, the other one third will receive Suppository Guaiacol and the last one third will receive Transpulmin Syrup.
Suppository Transpulmin, Suppository Guaiacol and Transpulmin Syrup are administered in the
treatment of cough with secretion of infectious origin.
Each Suppository Transpulmin contains eucalyptol, menthol, camphor and guaiacol. The main
pharmacological activity of eucalyptol occurs in the respiratory tract, playing expectorant
action, fluidity and antiseptic. There are indications that eucalyptol be a controller
inflammatory mediators, intervening directly in the pathophysiology of airway inflammation.
On the other hand, menthol has spasmolytic effect antiflatulent, antipruritic, analgesic and
antiemetic the mucosae, which has been shown in various studies in vitro and in vivo. In
addition, effective against many kinds of bacteria and fungi. Camphor, in turn, is used in
respiratory dysfunction due to secretolytic and antispasmodic properties (bronchi). Finally,
the guaiacol is classified as an expectorant because it believes that promote increased
sputum volume and decrease its viscosity, resulting in effective coughing. However, despite
its extensive use in recent decades, there are few randomized controlled trials demonstrating
its efficacy and tolerability, especially in pediatric participants.
Each Suppository Guaiacol contains guaiacol, whose action was explained previously.
Finally, each Transpulmin Syrup contains guaifenesin, which chemically it is a glyceryl ether
guaiacol. Thus, their structures are similar, and their pharmacological effects and
mechanisms of action. The addition of the hydroxyl group increases the hydrophilicity, making
the compound more soluble, thus being more suitable for pharmaceutical syrup form.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00116337 -
Spinal Cord Stimulation to Restore Cough
|
N/A | |
Not yet recruiting |
NCT04064333 -
Slow-Stream Expiratory Muscle Strength Training for Veterans With Dysphagia Living in Long-term Care
|
N/A | |
Recruiting |
NCT02482818 -
Efficacy of Pregabalin on Chronic Cough
|
Phase 1/Phase 2 | |
Terminated |
NCT02269761 -
Chest Ultrasound of ER Patients With Cough or SOB
|
||
Active, not recruiting |
NCT02065440 -
The Effect of Ebastine/Pseudoephedrine on Subacute Cough
|
N/A | |
Completed |
NCT01071161 -
The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough
|
Phase 3 | |
Completed |
NCT00353951 -
An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care
|
N/A | |
Terminated |
NCT00668317 -
Bronchial Hyper-responsiveness in Reflux Cough
|
Phase 3 | |
Completed |
NCT00127686 -
Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep
|
Phase 1 | |
Completed |
NCT00287339 -
The Utility of Nexium in Chronic Cough and Reflux Disease
|
Phase 4 | |
Recruiting |
NCT05115097 -
AI Evaluation of COVID-19 Sounds (AI-EChOS)
|
||
Recruiting |
NCT04457011 -
Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children
|
Phase 2 | |
Recruiting |
NCT05042063 -
Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
|
||
Recruiting |
NCT03922373 -
A Study of Benzonatate Soft Capsule in Chinese Healthy Subjects
|
Phase 1 | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Recruiting |
NCT04767074 -
A Non-pharmacological Cough Control Therapy
|
N/A | |
Recruiting |
NCT05570539 -
Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation
|
Phase 1 | |
Completed |
NCT03999203 -
A Cross-sectional Study to Measure Cough in Severe Asthma
|
N/A | |
Active, not recruiting |
NCT05479929 -
Work of Breathing Assessment in Triage Scale
|
||
Recruiting |
NCT02495571 -
Assessment of Voluntary and Reflex Cough in Patients With ALS
|
N/A |